merck glp 1 pays $112M upfront for Hansoh's preclinical GLP-1 GLP-1 weight-loss drugs are revolutionary

Original file (2,327 1,165 pixels, file size: 126 KB, MIME type: image/png) File information Structured data Captions Summary [edit] Licensing [edit] This file is licensed under the Creative Commons Attribution-Share Alike 2 } File history Click on a date/time to view the file as it appeared at that time

About type 1 diabetes For people with type 1 diabetes, the body does not produce insulin at all

Calcineurin inhibitors CsA use is associated with a dose-dependent increase in total cholesterol and low-density lipoprotein (LDL) cholesterol, a decrease in high-density lipoprotein (HDL) cholesterol, and an increase in serum triglycerides (202, 203)

Some injectable GLP-1 receptor agonists (such as liraglutide, dulaglutide, and injectable semaglutide) have demonstrated cardiovascular benefits in clinical trials

It is hard to know the true risk without adequate safety trials